The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment of advanced renal cell cancer.
Keytruda is an immunotherapy treatment that works by blocking a protein called PD-1 on the surface of certain immune cells called T cells, triggering the body’s immune system to kill cancer cells. It would be used in combination with Inlyta, which is already used to treat people with advanced kidney cancer whose cancer has continued to progress after initial treatment.
Original Article: NICE gives initial ‘no’ to NHS England for kidney cancer drug